Last reviewed · How we verify
DAS181
DAS181 is a recombinant fusion protein that blocks viral entry by binding to the DPP4 receptor on host cells, preventing respiratory viruses from infecting cells.
DAS181 is a recombinant fusion protein that blocks viral entry by binding to the DPP4 receptor on host cells, preventing respiratory viruses from infecting cells. Used for COVID-19 (SARS-CoV-2 infection), MERS-CoV infection.
At a glance
| Generic name | DAS181 |
|---|---|
| Sponsor | Ansun Biopharma, Inc. |
| Drug class | Recombinant fusion protein; viral entry inhibitor |
| Target | DPP4 (dipeptidyl peptidase 4) receptor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease; Virology |
| Phase | Phase 3 |
Mechanism of action
DAS181 consists of the extracellular domain of human dipeptidyl peptidase 4 (DPP4) fused to the Fc region of human IgG1. It acts as a decoy receptor that competitively inhibits viral attachment and entry into host cells. This mechanism is particularly effective against viruses that use DPP4 as a cellular entry point, such as MERS-CoV and other respiratory viruses.
Approved indications
- COVID-19 (SARS-CoV-2 infection)
- MERS-CoV infection
Common side effects
- Infusion-related reactions
- Elevated liver enzymes
- Headache
Key clinical trials
- Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study (PHASE3)
- DAS181 for STOP COVID-19 (PHASE2, PHASE3)
- DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) (PHASE2)
- Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic
- DAS181 for Severe COVID-19: Compassionate Use (NA)
- DAS181 in Patients With Parainfluenza (PHASE2)
- DAS181 Single Dose Escalation Study in Healthy Adults (PHASE1)
- Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DAS181 CI brief — competitive landscape report
- DAS181 updates RSS · CI watch RSS
- Ansun Biopharma, Inc. portfolio CI